logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
A

Arun Azad

university of melbourne

51H指数
518论文数
1.3W被引数
收录论文 166
发表时间
logo
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma动态免疫特征分析预测寡转移性肾细胞癌对放疗联合抗PD-1疗法的反应
errNature Communications
IF15.7
err2026-07-08
err0
errOAAI
errVan To; Niko Thio; Rebecca Castle; Sean Macdonald; Tristan Molden-Hauer; James Wells; Ryan McMahon; Mathias Bressel; Ben Tran; Arun A. Azad; Daniel Moon; Sree Appu; Lih-Ming Wong; Declan G. Murphy; Katharine Cuff; David Pryor; Lavinia Spain; Lewis Au; Criselle D’Souza; Paul J. Neeson; Shankar Siva
err分享
err收藏
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Saruparib与雄激素受体通路抑制剂联合治疗转移性激素敏感性前列腺癌：EvoPAR-Prostate01
errFuture Oncology
IF2.6
err2026-04-14
err0
PREAI
errArun A. Azad; Neeraj Agarwal; Andrew J. Armstrong; Eva Hellmis; Mikio Sugimoto; Yüksel Ürün; Nianzeng Xing; Mehreteab Aregay; Julianne Lima; Didier Meulendijks; Kim N. Chi
err分享
err收藏
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer指南之指南：177镥PSMA放射性配体治疗在晚期前列腺癌中的应用
errBJU International
IF4.4
err2026-04-14
err0
PREAI
errAbdullah Al-Khanaty; David Chen; Jonathan Walbaum; David Hennes; Carlos Delgado; Eoin Dinneen; Renu Eapen; Michael S. Hofman; Arun A. Azad; Declan G. Murphy; Nathan Lawrentschuk; Marlon Perera
err分享
err收藏
From salvage to spotlight: how 2025 transformed PSMA radioligand therapy从抢救到聚光灯：2025年如何改变了PSMA放射性配体疗法
errBJU International
IF4.4
err2026-04-14
err0
PREAI
errAbdullah Al-Khanaty; Carlos Delgado; Francisco Valencia; David Chen; Marlon L. Perera; Renu Eapen; Arun A. Azad; James P. Buteau; Michael S. Hofman; Declan G. Murphy
err分享
err收藏
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 TrialRe: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: 一项随机III期试验
errEuropean Urology
IF25.2
err2025-12-16
err0
PREAI
errJane McKenzie; Arun A. Azad
err分享
err收藏
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值：一项ProsTIC登记研究分析
errJOURNAL OF NUCLEAR MEDICINE
IF9.1
err2025-12-01
err1
PREAI
errChen, David C.; Buteau, James P.; Papa, Nathan; Akhurst, Tim; Alipour, Ramin; Bollampally, Neeraja; Cardin, Anthony; Eifer, Michal; Eliceiry, Sebastian Casanueva; Jackson, Price; Jewell, Kerry; Kashyap, Raghava; Kong, Grace; Kostos, Louise; Kumar, Aravind Ravi; Mcintosh, Lachlan; Medhurst, Elizabeth; Saghebi, Javad; Sandhu, Shahneen; Murphy, Declan G.; Tran, Ben; Azad, Arun A.; Hofman, Michael S.
err分享
err收藏
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy基于肿瘤的表观遗传学特征作为根治性前列腺切除术后前列腺癌侵袭性的标志物
errBritish Journal of Cancer
IF6.8
err2025-11-20
err0
PREAI
errYiyue Zhu; Elaheh Zarean; Danmeng L. Li; Robert L. O’Reilly; Ian D. Davis; Renea A. Taylor; Arun A. Azad; Damien M. Bolton; Nathan Papa; Nathan Lawrentschuk; Robert J. MacInnis; Roger L. Milne; Graham G. Giles; Melissa C. Southey; Pierre-Antoine Dugué
err分享
err收藏
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]勘误：Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析，来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]
errEuropean Journal of Cancer
IF7.1
err2025-11-13
err0
PREAI
errArun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
err分享
err收藏
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
errJOURNAL OF NUCLEAR MEDICINE
IF9.1
err2025-11-01
err0
PREAI
errJackson, Price; Buteau, James P.; McIntosh, Lachlan; Sun, Yu; Kashyap, Raghava; Casanueva, Sebastian; Kumar, Aravind S. Ravi; Sandhu, Shahneen; Azad, Arun A.; Alipour, Ramin; Saghebi, Javad; Kong, Grace; Jewell, Kerry; Eifer, Michal; Bollampally, Neeraja; Hofman, Michael S.
err分享
err收藏
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617基线和早期治疗时外周血循环肿瘤DNA比例是接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌的关键预后生物标志物
errEuropean Urology
IF25.2
err2025-10-29
err0
errOAAI
errHeidi Fettke; Louise Kostos; Maria Docanto; Patricia Bukczynska; Nicole Ng; Elizabeth Medhurst; Miyah Awad; James P. Buteau; Sebastián C. Eliceiry; Sathya Manoharan; Siavash Foroughi; Jason Steen; Tu Nguyen-Dumont; Michael S. Hofman; Arun A. Azad
err分享
err收藏
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial阿贝西利布联合阿比特龙在转移性去势抵抗性前列腺癌患者中的研究（CYCLONE 2）：一项随机、双盲、安慰剂对照、Ⅲ期临床试验
errThe Lancet Oncology
IF0
err2025-10-27
err0
PREAI
errMatthew Smith; Josep Piulats; Tilman Todenhöfer; Jae-Lyun Lee; José Arranz Arija; Laura Mazilu; Arun Azad; Teresa Alonso-Gordoa; Ursula McGovern; Atish Choudhury; Lisa Horvath; Dingwei Ye; Weiqing Han; Hiroyoshi Suzuki; Hiroji Uemura; Rana McKay; Steven Ades; Aude Fléchon; Christopher Pieczonka; Maria S Fernandes; Maarten Hulstijn; Andrew Lithio; Karim Nacerddine; Neeraj Agarwal
err分享
err收藏
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌（AlphaBet 研究）：一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析
errThe Lancet Oncology
IF0
err2025-10-18
err0
PREAI
errLouise Kostos; James P Buteau; Jing Xie; Anthony Cardin; Tim Akhurst; Ramin Alipour; Lewis Au; Joanna Chan; Kwang Y Chin; Brittany Emmerson; Luc Furic; Quinn Garcia; Anthony J Hamilton; Mohammad B Haskali; Price A Jackson; Raghava K Kashyap; Grace Kong; Lisa MacFarlane; Declan G Murphy; Belinda S Parker; Aravind S Ravi Kumar; Javad Saghebi; Yang Wang; Ben Tran; Arun A Azad; Michael S Hofman
err分享
err收藏
CONTACT-02: limited clinical benefit and a suboptimal control group – Authors' replyCONTACT-02：有限的临床获益和不理想的对照组——作者回复
errThe Lancet Oncology
IF0
err2025-09-29
err0
PREAI
errNeeraj Agarwal; Axel S Merseburger; Svetlana Andrianova; Arun A Azad
err分享
err收藏
Shaping the Future of 177Lu-PSMA-617 Radiopharmaceutical Therapy in Prostate Cancer: Is Earlier Better, or is Patient Selection Key?塑造177Lu-PSMA-617放射性药物疗法在前列腺癌中的未来：是更早治疗更好，还是患者选择是关键？
errAnnals of Oncology
IF65.4
err2025-09-11
err0
PREAI
errA.A. Azad; M.S. Hofman
err分享
err收藏
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialTalazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果：来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据
errlancet
IF0
err2025-07-16
err0
PREAI
errNeeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
err分享
err收藏
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialTalazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者：来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果
errlancet
IF0
err2025-07-16
err0
PREAI
errKarim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal
err分享
err收藏
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC恩扎卢胺与达罗鲁胺双药在mHSPC中的匹配调整间接比较
errFuture Oncology
IF2.6
err2025-07-14
err0
errOAAI
errAndrew J. Armstrong; Bhavik J. Pandya; Hemant Singh Bhadauria; Arijit Ganguli; Vagia Daki; Ana Moura; Arun A. Azad
err分享
err收藏
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果（VIOLET）：一项单中心、单臂、I/II期研究
errlancet oncology
IF0
err2025-07-03
err0
PREAI
errJames P Buteau; Louise Kostos; Price A Jackson; Jing Xie; Mohammad B Haskali; Ramin Alipour; Lachlan E McIntosh; Brittany Emmerson; Lisa MacFarlane; Claire A Martin; Joanna Chan; Sarah E Williams; Kerry E Jewell; Michal Eifer; Anthony J Hamilton; William Q Harris; Tim Akhurst; Lewis Au; Anthony J Cardin; Luc Furic; Raghava K Kashyap; Grace Kong; Aravind S Ravi Kumar; Declan G Murphy; Rajeev Ravi; Javad Saghebi; Shahneen Sandhu; Ben Tran; Arun A Azad; Michael S Hofman
err分享
err收藏
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review恩扎卢替尼治疗晚期前列腺癌患者的效果：通俗语言综述
errFuture Oncology
IF2.6
err2025-06-29
err0
errOAAI
errPaul E. Dato; Jose De La Cerda; Andrew J. Armstrong; Arun A. Azad; Ciara Conduit; Gabriel P. Haas; Kenneth Kernen; Zachary W. Klaassen; Raj Patel; Fred Saad; Neal D. Shore; Stephen J. Freedland; Lawrence I. Karsh
err分享
err收藏
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaR.E.N.A.L.复杂度评分对原发性肾细胞癌立体定向消融体部放射治疗效果的影响
errBJU International
IF4.4
err2025-06-28
err0
errOAAI
errMuhammad Ali; Mathias Bressel; David Chang; Sheng F. Oon; Rajeev Ravi; Daniel Moon; Declan G. Murphy; Renu S. Eapen; Marlon Perera; Nathan Lawrentschuk; Arun A. Azad; Sarat Chander; Mark Shaw; Nicholas Hardcastle; Shankar Siva
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
H
Howard I. Scher
H 指数: 164 · 论文数: 1.4K
J
Johann S. de Bono
H 指数: 160 · 论文数: 2.5K
R
Robert J. Motzer
H 指数: 148 · 论文数: 1.6K
J
John F. Thompson
H 指数: 136 · 论文数: 2.0K
F
Fred Saad
H 指数: 127 · 论文数: 1.9K
查看更多